As in pancreatic cancer, HER3 dimerized with EGFR and siRNA-mediated inhibition of HER3 expression showed acquired resistance to erlotinib, suggesting that lack of HER3 expression makes these cells less dependent on EGFR [75]. This evidence concerns the gene EGFR and pancreatic neoplasm.